{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T18:02:30Z","timestamp":1790791350853,"version":"4.1.0"},"reference-count":132,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,9,20]],"date-time":"2021-09-20T00:00:00Z","timestamp":1632096000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010256","name":"Guangzhou Municipal Science and Technology Project","doi-asserted-by":"publisher","award":["201804010086"],"award-info":[{"award-number":["201804010086"]}],"id":[{"id":"10.13039\/501100010256","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cardiovasc. Med."],"abstract":"<jats:p>The new guidelines classify heart failure (HF) into three subgroups based on the ejection fraction (EF): HF with reduced EF (HFrEF), HF with mid-range EF (HFmrEF), and HF with preserved EF (HFpEF). The new guidelines regarding the declaration of HFmrEF as a unique phenotype have achieved the goal of stimulating research on the basic characteristics, pathophysiology, and treatment of HF patients with a left ventricular EF of 40\u201349%. Patients with HFmrEF have more often been described as an intermediate population between HFrEF and HFpEF patients; however, with regard to etiology and clinical indicators, they are more similar to the HFrEF population. Concerning clinical prognosis, they are closer to HFpEF because both populations have a good prognosis and quality of life. Meanwhile, growing evidence indicates that HFmrEF and HFpEF show heterogeneity in presentation and pathophysiology, and the emergence of this heterogeneity often plays a crucial role in the prognosis and treatment of the disease. To date, the exact mechanisms and effective treatment strategies of HFmrEF and HFpEF are still poorly understood, but some of the current evidence, from observational studies and<jats:italic>post-hoc<\/jats:italic>analyses of randomized controlled trials, have shown that patients with HFmrEF may benefit more from HFrEF treatment strategies, such as beta-blockers, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, mineralocorticoid receptor antagonists, and sacubitril\/valsartan. This review summarizes available data from current clinical practice and mechanistic studies in terms of epidemiology, etiology, clinical indicators, mechanisms, and treatments to discuss the potential association between HFmrEF and HFpEF patients.<\/jats:p>","DOI":"10.3389\/fcvm.2021.678614","type":"journal-article","created":{"date-parts":[[2021,9,20]],"date-time":"2021-09-20T05:10:43Z","timestamp":1632114643000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":46,"title":["Similarities and Differences Between HFmrEF and HFpEF"],"prefix":"10.3389","volume":"8","author":[{"given":"Peixin","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hengli","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianyu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunshan","family":"Ning","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Tu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dingli","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingchun","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,9,20]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1093\/eurheartj\/ehw128","article-title":"2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: the task force for the diagnosis and treatment of acute and chronic heart failure of the European society of cardiology (ESC) Developed with the special contribution of the heart failure association (HFA) of the ESC","volume":"37","author":"Ponikowski","year":"2016","journal-title":"Eur Heart J"},{"key":"B2","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1002\/ejhf.592","article-title":"2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the heart failure association (HFA) of the ESC","volume":"18","author":"Ponikowski","year":"2016","journal-title":"Eur J Heart Fail"},{"key":"B3","doi-asserted-by":"publisher","first-page":"1574","DOI":"10.1002\/ejhf.813","article-title":"Epidemiology and one-year outcomes in patients with chronic heart failure and preserved, mid-range and reduced ejection fraction: an analysis of the ESC heart failure long-term registry","volume":"19","author":"Chioncel","year":"2017","journal-title":"Eur J Heart Fail."},{"key":"B4","doi-asserted-by":"publisher","first-page":"1252","DOI":"10.1136\/heartjnl-2018-314256","article-title":"Epidemiology and long-term outcome in outpatients with chronic heart failure in Northwestern Europe","volume":"105","author":"Frohlich","year":"2019","journal-title":"Heart"},{"key":"B5","doi-asserted-by":"publisher","first-page":"865","DOI":"10.3760\/cma.j.issn.0253-3758.2019.11.004","article-title":"Contemporary epidemiology and treatment of hospitalized heart failure patients in real clinical practice in China","volume":"47","author":"Wang","year":"2019","journal-title":"Zhonghua Xin Xue Guan Bing Za Zhi."},{"key":"B6","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.ejim.2018.11.001","article-title":"Patients with HFpEF and HFmrEF have different clinical characteristics in Turkey: a multicenter observational study","volume":"61","author":"Ozlek","year":"2019","journal-title":"Eur J Intern Med."},{"key":"B7","doi-asserted-by":"publisher","first-page":"e003875","DOI":"10.1161\/CIRCHEARTFAILURE.117.003875","article-title":"Significance of ischemic heart disease in patients with heart failure and preserved, midrange, and reduced ejection fraction: a nationwide cohort study","volume":"10","author":"Vedin","year":"2017","journal-title":"Circ Heart Fail."},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.rec.2020.09.033.","article-title":"Epidemiology and treatment of heart failure in Spain: the HF-PATHWAYS study","author":"Sicras-Mainar","year":"2020","journal-title":"Rev Esp Cardiol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1016\/j.jchf.2018.11.019","article-title":"Prevalence and prognostic implications of longitudinal ejection fraction change in heart failure","volume":"7","author":"Savarese","year":"2019","journal-title":"JACC Heart Fail"},{"key":"B10","first-page":"793","article-title":"Specialization and the trend towards professional independence in medicine from a historical viewpoint","volume":"108","author":"Vossschulte","year":"1966","journal-title":"Munch Med Wochenschr"},{"key":"B11","doi-asserted-by":"publisher","first-page":"3859","DOI":"10.1093\/eurheartj\/ehz835","article-title":"Sex differences in heart failure","volume":"40","author":"Lam","year":"2019","journal-title":"Eur Heart J"},{"key":"B12","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1016\/0002-9149(93)90678-6","article-title":"Sex differences in cardiac adaptation to isolated systolic hypertension","volume":"72","author":"Krumholz","year":"1993","journal-title":"Am J Cardiol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"1230","DOI":"10.1002\/ejhf.1149","article-title":"Heart failure with mid-range ejection fraction in CHARM: characteristics, outcomes and effect of candesartan across the entire ejection fraction spectrum","volume":"20","author":"Lund","year":"2018","journal-title":"Eur J Heart Fail."},{"key":"B14","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.1002\/ejhf.807","article-title":"Characterization of heart failure patients with mid-range left ventricular ejection fraction-a report from the CHART-2 study","volume":"19","author":"Tsuji","year":"2017","journal-title":"Eur J Heart Fail."},{"key":"B15","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1016\/j.ijcard.2018.01.119","article-title":"Bio-profiling and bio-prognostication of chronic heart failure with mid-range ejection fraction","volume":"257","author":"Moliner","year":"2018","journal-title":"Int J Cardiol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1016\/j.jchf.2017.12.014","article-title":"Utilizing NT-proBNP for eligibility and enrichment in trials in HFpEF, HFmrEF, and HFrEF","volume":"6","author":"Savarese","year":"2018","journal-title":"JACC Heart Fail."},{"key":"B17","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1016\/j.jchf.2017.04.007","article-title":"Biomarker profiles of acute heart failure patients with a mid-range ejection fraction","volume":"5","author":"Tromp","year":"2017","journal-title":"JACC Heart Fail."},{"key":"B18","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1093\/cvr\/cvaa023","article-title":"Coronary microvascular dysfunction in hypertrophy and heart failure","volume":"116","author":"Camici","year":"2020","journal-title":"Cardiovasc Res."},{"key":"B19","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.jacc.2013.02.092","article-title":"A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation","volume":"62","author":"Paulus","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"B20","doi-asserted-by":"crossref","first-page":"191","DOI":"10.59566\/IJBS.2011.7191","article-title":"Clinical study of advanced glycation end products in Egyptian diabetic obese and non-obese patients","volume":"7","author":"Amin","year":"2011","journal-title":"Int J Biomed Sci"},{"key":"B21","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.2337\/db11-0971","article-title":"Glycotoxin and autoantibodies are additive environmentally determined predictors of type 1 diabetes: a twin and population study","volume":"61","author":"Beyan","year":"2012","journal-title":"Diabetes"},{"key":"B22","first-page":"e157","article-title":"The role of Damage-Associated Molecular Patterns (DAMPs) in human diseases: part II: DAMPs as diagnostics, prognostics and therapeutics in clinical medicine","volume":"15","author":"Land","year":"2015","journal-title":"Sultan Qaboos Univ Med J"},{"key":"B23","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1007\/s00424-014-1480-8","article-title":"Heart failure with preserved ejection fraction","volume":"466","author":"Gladden","year":"2014","journal-title":"Pflugers Arch."},{"key":"B24","doi-asserted-by":"publisher","first-page":"242","DOI":"10.3390\/cells9010242","article-title":"Cellular and molecular differences between HFpEF and HFrEF: a step ahead in an improved pathological understanding","volume":"9","author":"Simmonds","year":"2020","journal-title":"Cells-Basel"},{"key":"B25","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1038\/cmi.2016.11","article-title":"Sterile signals generate weaker and delayed macrophage NLRP3 inflammasome responses relative to microbial signals","volume":"14","author":"Bezbradica","year":"2017","journal-title":"Cell Mol Immunol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1161\/CIRCRESAHA.115.307778","article-title":"Revisiting cardiac cellular composition","volume":"118","author":"Pinto","year":"2016","journal-title":"Circ Res"},{"key":"B27","doi-asserted-by":"publisher","first-page":"1792","DOI":"10.2337\/dc18-2515","article-title":"Microvascular disease in patients with diabetes with heart failure and reduced ejection versus preserved ejection fraction","volume":"42","author":"Tromp","year":"2019","journal-title":"Diabetes Care"},{"key":"B28","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1016\/j.jchf.2015.10.007","article-title":"Myocardial microvascular inflammatory endothelial activation in heart failure with preserved ejection fraction","volume":"4","author":"Franssen","year":"2016","journal-title":"JACC Heart Fail"},{"key":"B29","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1016\/j.jacc.2011.11.082","article-title":"Endothelial dysfunction, arterial stiffness, and heart failure","volume":"60","author":"Marti","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"B30","doi-asserted-by":"publisher","first-page":"2112","DOI":"10.1056\/NEJMe048269","article-title":"Nitroso-redox balance in the cardiovascular system","volume":"351","author":"Hare","year":"2004","journal-title":"N Engl J Med"},{"key":"B31","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1016\/j.jacc.2012.12.016","article-title":"Nitroso-redox imbalance affects cardiac structure and function","volume":"61","author":"Karantalis","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"B32","first-page":"433","article-title":"Biological markers of endothelial dysfunction in patients with heart failure","volume":"20","author":"Shakaryants","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"B33","doi-asserted-by":"publisher","first-page":"e010364","DOI":"10.1161\/JAHA.118.010364","article-title":"High-sensitivity troponin i in hospitalized and ambulatory patients with heart failure with preserved ejection fraction: insights from the heart failure clinical research network","volume":"7","author":"Fudim","year":"2018","journal-title":"J Am Heart Assoc"},{"key":"B34","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.jacc.2018.04.039","article-title":"Myocardial injury and cardiac reserve in patients with heart failure and preserved ejection fraction","volume":"72","author":"Obokata","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"B35","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1016\/j.bbadis.2018.08.005","article-title":"Early calcium handling imbalance in pressure overload-induced heart failure with nearly normal left ventricular ejection fraction","volume":"1865","author":"Rouhana","year":"2019","journal-title":"Biochim Biophys Acta Mol Basis Dis"},{"key":"B36","doi-asserted-by":"publisher","first-page":"2051","DOI":"10.1161\/CIRCULATIONAHA.107.716886","article-title":"Role of left ventricular stiffness in heart failure with normal ejection fraction","volume":"117","author":"Westermann","year":"2008","journal-title":"Circulation"},{"key":"B37","doi-asserted-by":"publisher","first-page":"1953","DOI":"10.1056\/NEJMoa032566","article-title":"Diastolic heart failure\u2014abnormalities in active relaxation and passive stiffness of the left ventricle","volume":"350","author":"Zile","year":"2004","journal-title":"N Engl J Med"},{"key":"B38","doi-asserted-by":"publisher","first-page":"3920195","DOI":"10.1155\/2017\/3920195","article-title":"A review of the molecular mechanisms underlying the development and progression of cardiac remodeling","volume":"2017","author":"Schirone","year":"2017","journal-title":"Oxid Med Cell Longev"},{"key":"B39","doi-asserted-by":"publisher","first-page":"2155","DOI":"10.1093\/eurheartj\/ehz158","article-title":"The continuous heart failure spectrum: moving beyond an ejection fraction classification","volume":"40","author":"Triposkiadis","year":"2019","journal-title":"Eur Heart J"},{"key":"B40","doi-asserted-by":"publisher","first-page":"1815","DOI":"10.1016\/j.jacc.2016.02.018","article-title":"Extracellular volume fraction for characterization of patients with heart failure and preserved ejection fraction","volume":"67","author":"Rommel","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"B41","doi-asserted-by":"publisher","first-page":"e005277","DOI":"10.1161\/CIRCIMAGING.116.005277","article-title":"Interstitial fibrosis, functional status, and outcomes in heart failure with preserved ejection fraction: insights from a prospective cardiac magnetic resonance imaging study","volume":"9","author":"Duca","year":"2016","journal-title":"Circ Cardiovasc Imaging"},{"key":"B42","doi-asserted-by":"publisher","first-page":"1877","DOI":"10.3390\/jcm8111877","article-title":"CMR tissue characterization in patients with HFmrEF","volume":"8","author":"Doeblin","year":"2019","journal-title":"J Clin Med"},{"key":"B43","doi-asserted-by":"publisher","first-page":"2449","DOI":"10.1016\/j.jacc.2015.04.026","article-title":"Circulating biomarkers of myocardial fibrosis: the need for a reappraisal","volume":"65","author":"Lopez","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"B44","doi-asserted-by":"publisher","first-page":"6976153","DOI":"10.1155\/2020\/6976153","article-title":"Type 2 diabetes mellitus and chronic heart failure with midrange and preserved ejection fraction: a focus on serum biomarkers of fibrosis","volume":"2020","author":"Lebedev","year":"2020","journal-title":"J Diabetes Res"},{"key":"B45","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1016\/0735-1097(89)90360-4","article-title":"Cardiac interstitium in health and disease: the fibrillar collagen network","volume":"13","author":"Weber","year":"1989","journal-title":"J Am Coll Cardiol"},{"key":"B46","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1016\/j.jacc.2010.10.024","article-title":"Diastolic tissue doppler indexes correlate with the degree of collagen expression and cross-linking in heart failure and normal ejection fraction","volume":"57","author":"Kasner","year":"2011","journal-title":"J Am Coll Cardiol"},{"key":"B47","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1161\/01.CIR.0000135591.37759.AF","article-title":"Altered titin expression, myocardial stiffness, and left ventricular function in patients with dilated cardiomyopathy","volume":"110","author":"Nagueh","year":"2004","journal-title":"Circulation"},{"key":"B48","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1161\/01.RES.0000117769.88862.F8","article-title":"The giant protein titin: a major player in myocardial mechanics, signaling, and disease","volume":"94","author":"Granzier","year":"2004","journal-title":"Circ Res"},{"key":"B49","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1093\/cvr\/cvs353","article-title":"Deranged myofilament phosphorylation and function in experimental heart failure with preserved ejection fraction","volume":"97","author":"Hamdani","year":"2013","journal-title":"Cardiovasc Res"},{"key":"B50","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1161\/CIRCRESAHA.117.311589","article-title":"Physiologic, pathologic, and therapeutic paracrine modulation of cardiac excitation-contraction coupling","volume":"122","author":"Mayourian","year":"2018","journal-title":"Circ Res"},{"key":"B51","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1038\/415198a","article-title":"Cardiac excitation-contraction coupling","volume":"415","author":"Bers","year":"2002","journal-title":"Nature"},{"key":"B52","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1007\/s10741-020-10042-0","article-title":"Mechanisms underlying the pathophysiology of heart failure with preserved ejection fraction: the tip of the iceberg","volume":"26","author":"Miranda-Silva","year":"2021","journal-title":"Heart Fail Rev"},{"key":"B53","doi-asserted-by":"publisher","first-page":"e004311","DOI":"10.1161\/CIRCHEARTFAILURE.117.004311","article-title":"Relaxation and the role of calcium in isolated contracting myocardium from patients with hypertensive heart disease and heart failure with preserved ejection fraction","volume":"10","author":"Runte","year":"2017","journal-title":"Circ Heart Fail"},{"key":"B54","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1161\/01.CIR.0000023042.50192.F4","article-title":"Rate dependence of [Na+]i and contractility in non-failing and failing human myocardium","volume":"106","author":"Pieske","year":"2002","journal-title":"Circulation"},{"key":"B55","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1016\/j.abb.2019.01.027","article-title":"Role of mitochondrial Ca(2+) homeostasis in cardiac muscles","volume":"663","author":"Cao","year":"2019","journal-title":"Arch Biochem Biophys"},{"key":"B56","doi-asserted-by":"publisher","first-page":"e13378","DOI":"10.1111\/apha.13378","article-title":"Disturbed cardiac mitochondrial and cytosolic calcium handling in a metabolic risk-related rat model of heart failure with preserved ejection fraction","volume":"228","author":"Miranda-Silva","year":"2020","journal-title":"Acta Physiol"},{"key":"B57","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1016\/j.hfc.2014.04.001","article-title":"Exercise physiology in heart failure and preserved ejection fraction","volume":"10","author":"Haykowsky","year":"2014","journal-title":"Heart Fail Clin"},{"key":"B58","doi-asserted-by":"publisher","first-page":"1435","DOI":"10.1161\/CIRCULATIONAHA.118.036259","article-title":"Mitochondrial dysfunction in heart failure with preserved ejection fraction","volume":"139","author":"Kumar","year":"2019","journal-title":"Circulation"},{"key":"B59","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1161\/CIRCRESAHA.113.300376","article-title":"Cardiac metabolism in heart failure: implications beyond ATP production","volume":"113","author":"Doenst","year":"2013","journal-title":"Circ Res"},{"key":"B60","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1161\/CIRCHEARTFAILURE.113.000250","article-title":"Molecular- and organelle-based predictive paradigm underlying recovery by left ventricular assist device support","volume":"7","author":"Liem","year":"2014","journal-title":"Circ Heart Fail"},{"key":"B61","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/j.jacc.2011.02.055","article-title":"Determinants of exercise intolerance in elderly heart failure patients with preserved ejection fraction","volume":"58","author":"Haykowsky","year":"2011","journal-title":"J Am Coll Cardiol"},{"key":"B62","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1016\/0735-1097(91)90832-T","article-title":"Exercise intolerance in patients with heart failure and preserved left ventricular systolic function: failure of the frank-starling mechanism","volume":"17","author":"Kitzman","year":"1991","journal-title":"J Am Coll Cardiol"},{"key":"B63","doi-asserted-by":"publisher","first-page":"2138","DOI":"10.1161\/CIRCULATIONAHA.106.632745","article-title":"Impaired chronotropic and vasodilator reserves limit exercise capacity in patients with heart failure and a preserved ejection fraction","volume":"114","author":"Borlaug","year":"2006","journal-title":"Circulation"},{"key":"B64","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.1093\/eurjhf\/hfr133","article-title":"Abnormal haemodynamic response to exercise in heart failure with preserved ejection fraction","volume":"13","author":"Bhella","year":"2011","journal-title":"Eur J Heart Fail"},{"key":"B65","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1161\/CIRCHEARTFAILURE.114.001615","article-title":"Exercise training in patients with heart failure and preserved ejection fraction: meta-analysis of randomized control trials","volume":"8","author":"Pandey","year":"2015","journal-title":"Circ Heart Fail"},{"key":"B66","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.jacc.2012.02.055","article-title":"Effect of endurance training on the determinants of peak exercise oxygen consumption in elderly patients with stable compensated heart failure and preserved ejection fraction","volume":"60","author":"Haykowsky","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"B67","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1093\/ehjci\/jez014","article-title":"Value of combined cardiopulmonary and echocardiography stress test to characterize the haemodynamic and metabolic responses of patients with heart failure and mid-range ejection fraction","volume":"20","author":"Pugliese","year":"2019","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"B68","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1093\/cvr\/cvp344","article-title":"Proteomic remodelling of mitochondrial oxidative pathways in pressure overload-induced heart failure","volume":"85","author":"Bugger","year":"2010","journal-title":"Cardiovasc Res"},{"key":"B69","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1002\/ejhf.239","article-title":"Heart failure with preserved ejection fraction induces molecular, mitochondrial, histological, and functional alterations in rat respiratory and limb skeletal muscle","volume":"17","author":"Bowen","year":"2015","journal-title":"Eur J Heart Fail"},{"key":"B70","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1113\/jphysiol.2003.045104","article-title":"Depressed mitochondrial transcription factors and oxidative capacity in rat failing cardiac and skeletal muscles","volume":"551","author":"Garnier","year":"2003","journal-title":"J Physiol"},{"key":"B71","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1093\/cvr\/cvn184","article-title":"Cardiac mitochondria in heart failure: decrease in respirasomes and oxidative phosphorylation","volume":"80","author":"Rosca","year":"2008","journal-title":"Cardiovasc Res"},{"key":"B72","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1016\/j.bbabio.2006.03.008","article-title":"Energy deficiency in the failing heart: linking increased reactive oxygen species and disruption of oxidative phosphorylation rate","volume":"1757","author":"Sheeran","year":"2006","journal-title":"Biochim Biophys Acta"},{"key":"B73","doi-asserted-by":"publisher","first-page":"2033","DOI":"10.1161\/CIRCULATIONAHA.106.668665","article-title":"Recruitment of compensatory pathways to sustain oxidative flux with reduced carnitine palmitoyltransferase I activity characterizes inefficiency in energy metabolism in hypertrophied hearts","volume":"115","author":"Sorokina","year":"2007","journal-title":"Circulation"},{"key":"B74","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1016\/j.yjmcc.2008.01.008","article-title":"Increased mitochondrial uncoupling proteins, respiratory uncoupling and decreased efficiency in the chronically infarcted rat heart","volume":"44","author":"Murray","year":"2008","journal-title":"J Mol Cell Cardiol"},{"key":"B75","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1016\/j.cjca.2017.03.009","article-title":"Complex energy metabolic changes in heart failure with preserved ejection fraction and heart failure with reduced ejection fraction","volume":"33","author":"De Jong","year":"2017","journal-title":"Can J Cardiol"},{"key":"B76","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/j.cmet.2014.12.011","article-title":"Mitochondrial fission and fusion factors reciprocally orchestrate mitophagic culling in mouse hearts and cultured fibroblasts","volume":"21","author":"Song","year":"2015","journal-title":"Cell Metab"},{"key":"B77","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1152\/physrev.00006.2004","article-title":"Myocardial substrate metabolism in the normal and failing heart","volume":"85","author":"Stanley","year":"2005","journal-title":"Physiol Rev"},{"key":"B78","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s10020-018-0005-x","article-title":"Uncoupling of glycolysis from glucose oxidation accompanies the development of heart failure with preserved ejection fraction","volume":"24","author":"Fillmore","year":"2018","journal-title":"Mol Med"},{"key":"B79","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1080\/13543784.2019.1657825","article-title":"Acetyl-CoA carboxylase (ACC) as a therapeutic target for metabolic syndrome and recent developments in ACC1\/2 inhibitors","volume":"28","author":"Chen","year":"2019","journal-title":"Expert Opin Investig Drugs"},{"key":"B80","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.yjmcc.2016.09.001","article-title":"Preservation of myocardial fatty acid oxidation prevents diastolic dysfunction in mice subjected to angiotensin II infusion","volume":"100","author":"Choi","year":"2016","journal-title":"J Mol Cell Cardiol"},{"key":"B81","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1016\/j.cmet.2016.12.022","article-title":"Multi-dimensional roles of ketone bodies in fuel metabolism, signaling, and therapeutics","volume":"25","author":"Puchalska","year":"2017","journal-title":"Cell Metab"},{"key":"B82","doi-asserted-by":"publisher","first-page":"68","DOI":"10.3389\/fcvm.2018.00068","article-title":"Loss of metabolic flexibility in the failing heart","volume":"5","author":"Karwi","year":"2018","journal-title":"Front Cardiovasc Med"},{"key":"B83","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1161\/CIRCULATIONAHA.115.017545","article-title":"Evidence for intramyocardial disruption of lipid metabolism and increased myocardial ketone utilization in advanced human heart failure","volume":"133","author":"Bedi","year":"2016","journal-title":"Circulation"},{"key":"B84","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1161\/CIRCULATIONAHA.115.017355","article-title":"The failing heart relies on ketone bodies as a fuel","volume":"133","author":"Aubert","year":"2016","journal-title":"Circulation"},{"key":"B85","doi-asserted-by":"publisher","first-page":"4243","DOI":"10.1093\/eurheartj\/ehy596","article-title":"Heart failure and diabetes: metabolic alterations and therapeutic interventions: a state-of-the-art review from the Translational research committee of the heart failure association-European society of cardiology","volume":"39","author":"Maack","year":"2018","journal-title":"Eur Heart J"},{"key":"B86","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1161\/CIRCRESAHA.120.317933","article-title":"Targeting mitochondria-inflammation circuit by beta-hydroxybutyrate mitigates HFpEF","volume":"128","author":"Deng","year":"2021","journal-title":"Circ Res"},{"key":"B87","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1002\/ehf2.12418","article-title":"Clinical characteristics of hospitalized heart failure patients with preserved, mid-range, and reduced ejection fractions in Japan","volume":"6","author":"Shiga","year":"2019","journal-title":"ESC Heart Fail"},{"key":"B88","doi-asserted-by":"publisher","first-page":"e18719","DOI":"10.1136\/bmjopen-2017-018719","article-title":"Clinical characteristics, one-year change in ejection fraction and long-term outcomes in patients with heart failure with mid-range ejection fraction: a multicentre prospective observational study in Catalonia (Spain)","volume":"7","author":"Farre","year":"2017","journal-title":"Bmj Open"},{"key":"B89","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1093\/eurheartj\/ehx564","article-title":"Beta-blockers for heart failure with reduced, mid-range, and preserved ejection fraction: an individual patient-level analysis of double-blind randomized trials","volume":"39","author":"Cleland","year":"2018","journal-title":"Eur Heart J"},{"key":"B90","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1093\/eurheartj\/ehx663","article-title":"Beta-blockers for the treatment of heart failure with a mid-range ejection fraction: deja-vu all over again?","volume":"39","author":"Wilcox","year":"2018","journal-title":"Eur Heart J"},{"key":"B91","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1177\/2048872619827476","article-title":"Beta-blockers for post-acute coronary syndrome mid-range ejection fraction: a nationwide retrospective study","volume":"8","author":"Montenegro","year":"2019","journal-title":"Eur Heart J Acute Cardiovasc Care"},{"key":"B92","doi-asserted-by":"publisher","first-page":"203","DOI":"10.3390\/jcm10020203","article-title":"Treatment of heart failure with mid-range ejection fraction: what is the evidence","volume":"10","author":"Koufou","year":"2021","journal-title":"J Clin Med"},{"key":"B93","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00392-017-1170-6","article-title":"Heart failure with preserved ejection fraction: current management and future strategies: expert opinion on the behalf of the nucleus of the \u201cheart failure working group\u201d of the German society of cardiology. (DKG)","volume":"107","author":"Tschope","year":"2018","journal-title":"Clin Res Cardiol"},{"key":"B94","doi-asserted-by":"publisher","first-page":"1787","DOI":"10.1093\/eurheartj\/ehs104","article-title":"ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: the task force for the diagnosis and treatment of acute and chronic heart failure 2012 of the European society of cardiology. Developed in collaboration with the heart failure association (HFA) of the ESC","volume":"33","author":"McMurray","year":"2012","journal-title":"Eur Heart J"},{"key":"B95","doi-asserted-by":"publisher","first-page":"9","DOI":"10.15420\/cfr.2018:10:1","article-title":"Heart failure with mid-range ejection fraction and how to treat it","volume":"4","author":"Lopatin","year":"2018","journal-title":"Card Fail Rev"},{"key":"B96","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1002\/ejhf.1531","article-title":"Clinical practice update on heart failure 2019: pharmacotherapy, procedures, devices and patient management. An expert consensus meeting report of the heart failure association of the European society of cardiology","volume":"21","author":"Seferovic","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"B97","doi-asserted-by":"publisher","first-page":"1624","DOI":"10.1002\/ejhf.945","article-title":"A comprehensive population-based characterization of heart failure with mid-range ejection fraction","volume":"19","author":"Koh","year":"2017","journal-title":"Eur J Heart Fail"},{"key":"B98","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1136\/hrt.2007.117978","article-title":"The Hong Kong diastolic heart failure study: a randomised controlled trial of diuretics, irbesartan and ramipril on quality of life, exercise capacity, left ventricular global and regional function in heart failure with a normal ejection fraction","volume":"94","author":"Yip","year":"2008","journal-title":"Heart"},{"key":"B99","doi-asserted-by":"publisher","first-page":"2456","DOI":"10.1056\/NEJMoa0805450","article-title":"Irbesartan in patients with heart failure and preserved ejection fraction","volume":"359","author":"Massie","year":"2008","journal-title":"N Engl J Med"},{"key":"B100","doi-asserted-by":"publisher","first-page":"e14967","DOI":"10.1097\/MD.0000000000014967","article-title":"Efficacy and safety of spironolactone in the heart failure with mid-range ejection fraction and heart failure with preserved ejection fraction: a meta-analysis of randomized clinical trials","volume":"98","author":"Xiang","year":"2019","journal-title":"Medicine"},{"key":"B101","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1093\/eurheartj\/ehv464","article-title":"Influence of ejection fraction on outcomes and efficacy of spironolactone in patients with heart failure with preserved ejection fraction","volume":"37","author":"Solomon","year":"2016","journal-title":"Eur Heart J"},{"key":"B102","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1002\/ehf2.12571","article-title":"Spironolactone use is associated with improved outcomes in heart failure with mid-range ejection fraction","volume":"7","author":"Enzan","year":"2020","journal-title":"ESC Heart Fail"},{"key":"B103","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1080\/03007995.2018.1520695","article-title":"Outcomes of spironolactone treatment in patients in Northeast China suffering from heart failure with mid-range ejection fraction","volume":"35","author":"Xin","year":"2019","journal-title":"Curr Med Res Opin"},{"key":"B104","doi-asserted-by":"publisher","first-page":"e6125","DOI":"10.1161\/CIRCHEARTFAILURE.119.006125","article-title":"Utility of the cardiovascular physical examination and impact of spironolactone in heart failure with preserved ejection fraction","volume":"12","author":"Selvaraj","year":"2019","journal-title":"Circ Heart Fail"},{"key":"B105","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1056\/NEJMoa1409077","article-title":"Angiotensin-neprilysin inhibition versus enalapril in heart failure","volume":"371","author":"McMurray","year":"2014","journal-title":"N Engl J Med"},{"key":"B106","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.1056\/NEJMoa1908655","article-title":"Angiotensin-neprilysin inhibition in heart failure with preserved ejection fraction","volume":"381","author":"Solomon","year":"2019","journal-title":"N Engl J Med"},{"key":"B107","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1016\/j.hlc.2020.10.012","article-title":"The effect of sacubitril-valsartan in heart failure patients with mid-range and preserved ejection fraction: a meta-analysis","volume":"30","author":"Nie","year":"2020","journal-title":"Heart Lung Circ"},{"key":"B108","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.1056\/NEJM199811053391902","article-title":"Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels","volume":"339","year":"1998","journal-title":"N Engl J Med"},{"key":"B109","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1056\/NEJM199610033351401","article-title":"The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and recurrent events trial investigators","volume":"335","author":"Sacks","year":"1996","journal-title":"N Engl J Med"},{"key":"B110","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/S0140-6736(02)09327-3","article-title":"MRC\/BHF heart protection study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial","volume":"360","year":"2002","journal-title":"Lancet"},{"key":"B111","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1161\/CIRCHEARTFAILURE.115.002143","article-title":"Association Between use of statins and mortality in patients with heart failure and ejection fraction of \u226550","volume":"8","author":"Alehagen","year":"2015","journal-title":"Circ Heart Fail"},{"key":"B112","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1007\/s00125-016-4134-x","article-title":"Empagliflozin decreases myocardial cytoplasmic Na(+) through inhibition of the cardiac Na(+)\/H(+) exchanger in rats and rabbits","volume":"60","author":"Baartscheer","year":"2017","journal-title":"Diabetologia"},{"key":"B113","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1161\/CIRCULATIONAHA.117.029529","article-title":"Effects of the selective sodium-glucose cotransporter 2 inhibitor empagliflozin on vascular function and central hemodynamics in patients with type 2 diabetes mellitus","volume":"136","author":"Striepe","year":"2017","journal-title":"Circulation"},{"key":"B114","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1016\/j.cjca.2019.08.033","article-title":"Direct effects of empagliflozin on extracellular matrix remodelling in human cardiac myofibroblasts: novel translational clues to explain EMPA-REG OUTCOME results","volume":"36","author":"Kang","year":"2020","journal-title":"Can J Cardiol"},{"key":"B115","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1186\/s12933-018-0775-z","article-title":"Impact of dapagliflozin on left ventricular diastolic function of patients with type 2 diabetic mellitus with chronic heart failure","volume":"17","author":"Soga","year":"2018","journal-title":"Cardiovasc Diabetol"},{"key":"B116","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N Engl J Med"},{"key":"B117","doi-asserted-by":"publisher","first-page":"2528","DOI":"10.1161\/CIRCULATIONAHA.119.040130","article-title":"Effect of dapagliflozin on heart failure and mortality in type 2 diabetes mellitus","volume":"139","author":"Kato","year":"2019","journal-title":"Circulation"},{"key":"B118","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.jacbts.2018.11.010","article-title":"Empagliflozin improves diastolic function in a nondiabetic rodent model of heart failure with preserved ejection fraction","volume":"4","author":"Connelly","year":"2019","journal-title":"JACC Basic Transl Sci"},{"key":"B119","doi-asserted-by":"publisher","first-page":"2108","DOI":"10.1093\/cvr\/cvaa256","article-title":"The effects of liraglutide and dapagliflozin on cardiac function and structure in a multi-hit mouse model of heart failure with preserved ejection fraction","volume":"117","author":"Withaar","year":"2020","journal-title":"Cardiovasc Res"},{"key":"B120","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1536\/ihj.18-392","article-title":"Inhibitory effects of tofogliflozin on cardiac hypertrophy in dahl salt-sensitive and salt-resistant rats fed a high-fat diet","volume":"60","author":"Kimura","year":"2019","journal-title":"Int Heart J"},{"key":"B121","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1007\/s11897-014-0219-3","article-title":"New insights in (inter)cellular mechanisms by heart failure with preserved ejection fraction","volume":"11","author":"Tschope","year":"2014","journal-title":"Curr Heart Fail Rep"},{"key":"B122","doi-asserted-by":"publisher","first-page":"2263","DOI":"10.1161\/CIRCULATIONAHA.110.981738","article-title":"Soluble guanylate cyclase as an emerging therapeutic target in cardiopulmonary disease","volume":"123","author":"Stasch","year":"2011","journal-title":"Circulation"},{"key":"B123","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1093\/eurheartj\/ehw593","article-title":"Vericiguat in patients with worsening chronic heart failure and preserved ejection fraction: results of the SOluble guanylate Cyclase stimulatoR in heArT failurE patientS with PRESERVED EF (SOCRATES-PRESERVED) study","volume":"38","author":"Pieske","year":"2017","journal-title":"Eur Heart J"},{"key":"B124","doi-asserted-by":"publisher","first-page":"1512","DOI":"10.1001\/jama.2020.15922","article-title":"Effect of vericiguat vs placebo on quality of life in patients with heart failure and preserved ejection fraction: the VITALITY-HFpEF randomized clinical trial","volume":"324","author":"Armstrong","year":"2020","journal-title":"JAMA"},{"key":"B125","doi-asserted-by":"publisher","first-page":"1883","DOI":"10.1056\/NEJMoa1915928","article-title":"Vericiguat in patients with heart failure and reduced ejection fraction","volume":"382","author":"Armstrong","year":"2020","journal-title":"N Engl J Med"},{"key":"B126","doi-asserted-by":"publisher","first-page":"1795","DOI":"10.1016\/j.jacc.2020.08.031","article-title":"Targeting cyclic guanosine monophosphate to treat heart failure: JACC review topic of the week","volume":"76","author":"Emdin","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"B127","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1007\/s00059-015-4362-8","article-title":"Cardiac contractility modulation. A new form of therapy for patients with heart failure and narrow QRS complex?","volume":"40","author":"Kleemann","year":"2015","journal-title":"Herz"},{"key":"B128","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1007\/s00392-017-1135-9","article-title":"Clinical effects of long-term cardiac contractility modulation (CCM) in subjects with heart failure caused by left ventricular systolic dysfunction","volume":"106","author":"Muller","year":"2017","journal-title":"Clin Res Cardiol"},{"key":"B129","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1016\/j.jcmg.2009.07.011","article-title":"Impact of cardiac contractility modulation on left ventricular global and regional function and remodeling","volume":"2","author":"Yu","year":"2009","journal-title":"JACC Cardiovasc Imaging"},{"key":"B130","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1016\/j.jchf.2018.04.010","article-title":"A randomized controlled trial to evaluate the safety and efficacy of cardiac contractility modulation","volume":"6","author":"Abraham","year":"2018","journal-title":"JACC Heart Fail"},{"key":"B131","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1002\/ejhf.1349","article-title":"Cardiac contractility modulation: mechanisms of action in heart failure with reduced ejection fraction and beyond","volume":"21","author":"Tschope","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"B132","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1016\/j.ijcard.2015.10.208","article-title":"Cardiac contractility modulation signals improve exercise intolerance and maladaptive regulation of cardiac key proteins for systolic and diastolic function in HFpEF","volume":"203","author":"Tschope","year":"2016","journal-title":"Int J Cardiol"}],"container-title":["Frontiers in Cardiovascular Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2021.678614\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,9]],"date-time":"2023-11-09T01:08:22Z","timestamp":1699492102000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2021.678614\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,20]]},"references-count":132,"alternative-id":["10.3389\/fcvm.2021.678614"],"URL":"https:\/\/doi.org\/10.3389\/fcvm.2021.678614","relation":{},"ISSN":["2297-055X"],"issn-type":[{"value":"2297-055X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,20]]},"article-number":"678614"}}